We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Assessing Ocular Surface Changes After Changing Glaucoma Medications

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00554411
Recruitment Status : Completed
First Posted : November 6, 2007
Last Update Posted : January 27, 2017
Information provided by (Responsible Party):
University of Colorado, Denver

November 2, 2007
November 6, 2007
January 27, 2017
November 2007
August 2011   (Final data collection date for primary outcome measure)
Change in Signs and Symptoms of Ocular Surface Disease [ Time Frame: 6 months ]
measurable change in the tear film brek up time [ Time Frame: 6 weeks ]
Complete list of historical versions of study NCT00554411 on ClinicalTrials.gov Archive Site
Not Provided
measurable change in the corneal staining and the Ocular Surface Disease Index [ Time Frame: 6 weeks ]
Not Provided
Not Provided
Assessing Ocular Surface Changes After Changing Glaucoma Medications
Assessing Changes at the Ocular Surface Following the Switch From Xalatan to Travatan Z.
Hypothesis: Changing to Travatan Z therapy increases the tear film break up time of subjects on Xalatan therapy presenting with ocular surface disease.
Patients who have been taking Xalatan monotherapy to treat their glaucoma and presenting with ocular surface disease will be advised to switch their medication to Travatan Z. Test results will be recorded at the day that the medication was changed and at follow-up to determine if there is a measurable change in tear film break up, corneal staining and in the Ocular Surface Disease Index.
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
patients will be selected from the ophthalmology clinic of the principal investigator
  • Glaucoma
  • Monotherapy With Xalatan From 1 to 18 Months
  • Ocular Surface Disease
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
August 2011
August 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • on Xalatan monotherapy from 1 to 18 months
  • 18 years of age or older
  • has been diagnosed with ocular surface disease

Exclusion Criteria:

  • special populations such as children, pregnant females, prisoners, etc.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Plan to Share IPD: No
University of Colorado, Denver
University of Colorado, Denver
Not Provided
Principal Investigator: Malik Y Kahook, M.D. Rocky mountain Lions Eye Institute
University of Colorado, Denver
January 2017